SEARCH

SEARCH BY CITATION

References

  • 1
    Kirkpatrick P, Riminton S. Primary immunodeficiency diseases in Australia and New Zealand. J Clin Immunol 2007; 27:517524.
  • 2
    Rhim JW, Kim KH, Kim DS et al. Prevalence of primary immunodeficiency in Korea. J Korean Med Sci 2012; 27:788793.
  • 3
    Ishimura M, Takada H, Doi T et al. Nationwide survey of patients with primary immunodeficiency diseases in Japan. J Clin Immunol 2011; 31:968976.
  • 4
    Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999; 92:3448.
  • 5
    Park JH, Resnick ES, Cunningham-Rundles C. Perspectives on common variable immune deficiency. Ann NY Acad Sci 2011; 1246:4149.
  • 6
    van Zelm MC, Reisli I, van der Burg M et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 2006; 354:19011912.
  • 7
    Grimbacher B, Hutloff A, Schlesier M et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol 2003; 4:261268.
  • 8
    Kuijpers TW, Bende RJ, Baars PA et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest 2010; 120:214222.
  • 9
    van Zelm MC, Smet J, Adams B et al. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest 2010; 120:12651274.
  • 10
    Al-Herz W, Bousfiha A, Casanova JL et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Front Immunol 2011; 2:54. doi: 10.3389/fimmu.2011.00054.
  • 11
    Pan-Hammarstrom Q, Salzer U, Du L et al. Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. Nat Genet 2007; 39:429430.
  • 12
    Sekine H, Ferreira RC, Pan-Hammarstrom Q et al. Role for Msh5 in the regulation of Ig class switch recombination. Proc Natl Acad Sci USA 2007; 104:71937198.
  • 13
    Koopmans W, Woon ST, Brooks AE, Dunbar PR, Browett P, Ameratunga R. Clinical variability of family members with the C104R mutation in transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). J Clin Immunol 2013; 33:6873.
  • 14
    Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999; 93:190197.
  • 15
    Quinti I, Soresina A, Guerra A et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol 2011; 31:315322.
  • 16
    Katz U, Shoenfeld Y, Zandman-Goddard G. Update on intravenous immunoglobulins (IVIg) mechanisms of action and off-label use in autoimmune diseases. Curr Pharm Des 2011; 17:31663175.
  • 17
    Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012; 367:20152025.
  • 18
    Ameratunga R, Woon ST, Brewerton M et al. Primary immune deficiency disorders in the South Pacific: the clinical utility of a customized genetic testing program in New Zealand. Ann NY Acad Sci 2011; 1238:5364.
  • 19
    Gelfand EW, Ochs HD, Shearer WT. Controversies in IgG replacement therapy in patients with antibody deficiency diseases. J Allergy Clin Immunol 2013; 131:10011005.
  • 20
    Agarwal S, Cunningham-Rundles C. Treatment of hypogammaglobulinemia in adults: a scoring system to guide decisions on immunoglobulin replacement. J Allergy Clin Immunol 2013; 131:16991701.
  • 21
    Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol 2009; 145:709727.
  • 22
    Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference distributions for immunoglobulins A, G, and M: a practical, simple, and clinically relevant approach in a large cohort. J Clin Lab Anal 1998; 12:363370.
  • 23
    Orange JS, Ballow M, Stiehm ER et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2012; 130:S124.
  • 24
    Empson M, Sinclair J, O'Donnell J, Ameratunga R, Fitzharris P, Steele R. The assessment and management of primary antibody deficiency. NZ Med J 2004; 117:U914.
  • 25
    Goldacker S, Draeger R, Warnatz K et al. Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol 2007; 124:294303.
  • 26
    Thierry-Carstensen B, Jordan K, Uhlving HH et al. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults. Vaccine 2012; 30:54645471.
  • 27
    Hawdon N, Nix EB, Tsang RS, Ferroni G, McCready WG, Ulanova M. Immune response to Haemophilus influenzae type B vaccination in patients with chronic renal failure. Clin Vaccine Immunol 2012; 19:967969.
  • 28
    Dentinger CM, Hennessy TW, Bulkow LR et al. Immunogenicity and reactogenicity to Haemophilus influenzae type B (Hib) conjugate vaccine among rural Alaska adults. Hum Vaccin 2006; 2:2428.
  • 29
    Ameratunga SN, Lennon DR, Entwistle B, Robinson E, Ameratunga RV. The immunogenicity of Haemophilus influenzae: meningococcal protein conjugate vaccine in Polynesian and non-Polynesian New Zealand infants. J Paediatr Child Health 1997; 33:138141.
  • 30
    Ladhani S, Ramsay M, Flood J et al. Haemophilus influenzae serotype B (Hib) seroprevalence in England and Wales in 2009. Euro Surveill 2012; 17:pii: 20313.
  • 31
    O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007; 7:597606.
  • 32
    Tiller TL Jr, Buckley RH. Transient hypogammaglobulinemia of infancy: review of the literature, clinical and immunologic features of 11 new cases, and long-term follow-up. J Pediatr 1978; 92:347353.
  • 33
    Lee H, Nahm MH, Kim KH. The effect of age on the response to the pneumococcal polysaccharide vaccine. BMC Infect Dis 2010; 10:60.
  • 34
    Henckaerts I, Goldblatt D, Ashton L, Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 2006; 13:356360.
  • 35
    Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal–polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001; 8:266272.
  • 36
    Ballow M. Vaccines in the assessment of patients for immune deficiency. J Allergy Clin Immunol 2012; 130:283284 e5.
  • 37
    Balloch A, Licciardi PV, Tang ML. Serotype-specific anti-pneumococcal IgG and immune competence: critical differences in interpretation criteria when different methods are used. J Clin Immunol 2013; 33:335341.
  • 38
    Russell FM, Carapetis JR, Burton RL et al. Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age. Vaccine 2011; 29:535544.
  • 39
    Romero-Steiner S, Frasch CE, Carlone G, Fleck RA, Goldblatt D, Nahm MH. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 2006; 13:165169.
  • 40
    Cavaliere FM, Milito C, Martini H et al. Quantification of IgM and IgA anti-pneumococcal capsular polysaccharides by a new ELISA assay: a valuable diagnostic and prognostic tool for common variable immunodeficiency. J Clin Immunol 2013; 33:838846.
  • 41
    Sorensen RU, Leiva LE, Javier FC III et al. Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations. J Allergy Clin Immunol 1998; 102:215221.
  • 42
    Bonilla FA, Bernstein IL, Khan DA et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005; 94:S163.
  • 43
    Paris K, Sorensen RU. Assessment and clinical interpretation of polysaccharide antibody responses. Ann Allergy Asthma Immunol 2007; 99:462464.
  • 44
    Jodar L, Butler J, Carlone G et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003; 21:32653272.
  • 45
    Lee LH, Frasch CE, Falk LA, Klein DL, Deal CD. Correlates of immunity for pneumococcal conjugate vaccines. Vaccine 2003; 21:21902196.
  • 46
    Jokinen JT, Ahman H, Kilpi TM, Makela PH, Kayhty MH. Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. J Infect Dis 2004; 190:545550.
  • 47
    Hare ND, Smith BJ, Ballas ZK. Antibody response to pneumococcal vaccination as a function of preimmunization titer. J Allergy Clin Immunol 2009; 123:195200.
  • 48
    Ferry BL, Misbah SA, Stephens P et al. Development of an anti-Salmonella typhi Vi ELISA: assessment of immunocompetence in healthy donors. Clin Exp Immunol 2004; 136:297303.
  • 49
    Rezaei N, Siadat SD, Aghamohammadi A et al. Serum bactericidal antibody response 1 year after meningococcal polysaccharide vaccination of patients with common variable immunodeficiency. Clin Vaccine Immunol 2010; 17:524528.
  • 50
    Brinkman DM, Jol-van der Zijde CM, ten Dam MM et al. Vaccination with rabies to study the humoral and cellular immune response to a T-cell dependent neoantigen in man. J Clin Immunol 2003; 23:528538.
  • 51
    Ochs HD, Davis SD, Wedgwood RJ. Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases. J Clin Invest 1971; 50:25592568.
  • 52
    Agarwal S, Cunningham-Rundles C. Assessment and clinical interpretation of reduced IgG values. Ann Allergy Asthma Immunol 2007; 99:281283.
  • 53
    Smith J, Fernando T, McGrath N, Ameratunga R. Lamotrigine-induced common variable immune deficiency. Neurology 2004; 62:833834.
  • 54
    Hermaszewski RA, Webster AD. Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications. Q J Med 1993; 86:3142.
  • 55
    Quinti I, Soresina A, Spadaro G et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol 2007; 27:308316.
  • 56
    Chapel H, Lucas M, Lee M et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008; 112:277286.
  • 57
    Oksenhendler E, Gerard L, Fieschi C et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis 2008; 46:15471554.
  • 58
    Knight AK, Cunningham-Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev 2006; 5:156159.
  • 59
    Wehr C, Kivioja T, Schmitt C et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 2008; 111:7785.
  • 60
    Abrahamian F, Agrawal S, Gupta S. Immunological and clinical profile of adult patients with selective immunoglobulin subclass deficiency: response to intravenous immunoglobulin therapy. Clin Exp Immunol 2010; 159:344350.
  • 61
    Olinder-Nielsen AM, Granert C, Forsberg P, Friman V, Vietorisz A, Bjorkander J. Immunoglobulin prophylaxis in 350 adults with IgG subclass deficiency and recurrent respiratory tract infections: a long-term follow-up. Scand J Infect Dis 2007; 39:4450.
  • 62
    Musher DM, Manof SB, Liss C et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010; 201:516524.
  • 63
    Salzer U, Bacchelli C, Buckridge S et al. Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes. Blood 2009; 113:19671976.
  • 64
    Popa V. Lymphocytic interstitial pneumonia of common variable immunodeficiency. Ann Allergy 1988; 60:203206.
  • 65
    Ameratunga R, Becroft DM, Hunter W. The simultaneous presentation of sarcoidosis and common variable immune deficiency. Pathology 2000; 32:280282.
  • 66
    Fasano MB, Sullivan KE, Sarpong SB et al. Sarcoidosis and common variable immunodeficiency. Report of 8 cases and review of the literature. Medicine (Balt) 1996; 75:251261.
  • 67
    Fuss IJ, Friend J, Yang Z et al. Nodular regenerative hyperplasia in common variable immunodeficiency. J Clin Immunol 2013; 33:748758.
  • 68
    Malamut G, Ziol M, Suarez F et al. Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J Hepatol 2008; 48:7482.
  • 69
    Luzi G, Zullo A, Iebba F et al. Duodenal pathology and clinical–immunological implications in common variable immunodeficiency patients. Am J Gastroenterol 2003; 98:118121.
    Direct Link:
  • 70
    Malamut G, Verkarre V, Suarez F et al. The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease. Am J Gastroenterol 2010; 105:22622275.
  • 71
    Agarwal S, Smereka P, Harpaz N, Cunningham-Rundles C, Mayer L. Characterization of immunologic defects in patients with common variable immunodeficiency (CVID) with intestinal disease. Inflamm Bowel Dis 2011; 17:251259.
  • 72
    Hill AT, Pasteur M, Cornford C, Welham S, Bilton D. Primary care summary of the British Thoracic Society Guideline on the management of non-cystic fibrosis bronchiectasis. Prim Care Respir J 2011; 20:135140.
  • 73
    Koopmans W, Woon ST, Zeng IS et al. Variability of memory B cell markers in a cohort of common variable immune deficiency patients over six months. Scand J Immunol 2013; 77:470475.
  • 74
    Orange JS, Glessner JT, Resnick E et al. Genome-wide association identifies diverse causes of common variable immunodeficiency. J Allergy Clin Immunol 2011; 127:13601376.
  • 75
    Biagi F, Bianchi PI, Zilli A et al. The significance of duodenal mucosal atrophy in patients with common variable immunodeficiency: a clinical and histopathologic study. Am J Clin Pathol 2012; 138:185189.
  • 76
    Ameratunga R, Casey P, Parry S et al. Hypogammaglobulinemia factitia: Munchausen syndrome masquerading as common variable immune deficiency. Allergy Asthma Clin Immunol 2013 (in press).